The effectiveness, feasibility and acceptability of HIV service delivery at private pharmacies in sub‐Saharan Africa: a scoping review

• Published in: Journal of the International AIDS Society 2022-10, Vol.25 (10), p.e26027-n/a
• Main Authors: Kuo, Alexandra P., Roche, Stephanie D., Mugambi, Melissa L., Pintye, Jillian, Baeten, Jared M., Bukusi, Elizabeth, Ngure, Kenneth, Stergachis, Andy, Ortblad, Katrina F.
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Antiretroviral agents; ART delivery; Drug stores; Feasibility Studies; HIV; HIV Infections - diagnosis; HIV Infections - drug therapy; HIV Infections - prevention & control; HIV testing; Human immunodeficiency virus; Humans; Kenya; Pharmacies; Pre-Exposure Prophylaxis - methods; PrEP delivery; Privacy; private pharmacies; Prophylaxis; Review; Reviews; scoping review; sub‐Saharan Africa
• ISSN: 1758-2652; 1758-2652
• DOI: 10.1002/jia2.26027

Introduction Private pharmacies are an understudied setting for differentiated delivery of HIV services that may address barriers to clinic‐delivered services, such as stigma and long wait times. To understand the potential for pharmacy‐delivered HIV services in sub‐Saharan Africa, we conducted a scoping review of the published and grey literature. Methods Using a modified Cochrane approach, we searched electronic databases through March 2022 and HIV conference s in the past 5 years for studies that: (1) focused on the delivery of HIV testing, antiretroviral therapy (ART) and/or pre‐exposure prophylaxis (PrEP) at private pharmacies in sub‐Saharan Africa; (2) reported on effectiveness outcomes (e.g. HIV incidence) or implementation outcomes, specifically feasibility and/or acceptability; and (3) were published in English. Two authors identified studies and extracted data on study setting, population, design, outcomes and findings by HIV service type. Results and discussion Our search identified 1646 studies. After screening and review, we included 28 studies: seven on HIV testing, nine on ART delivery and 12 on PrEP delivery. Most studies (n = 16) were conducted in East Africa, primarily in Kenya. Only two studies evaluated effectiveness outcomes; the majority (n = 26) reported on feasibility and/or acceptability outcomes. The limited effectiveness data (n = 2 randomized trials) suggest that pharmacy‐delivered HIV services can increase demand and result in comparable clinical outcomes (e.g. viral load suppression) to standard‐of‐care clinic‐based models. Studies assessing implementation outcomes found actual and hypothetical models of pharmacy‐delivered HIV services to be largely feasible (e.g. high initiation and continuation) and acceptable (e.g. preferable to facility‐based models and high willingness to pay/provide) among stakeholders, providers and clients. Potential barriers to implementation included a lack of pharmacy provider training on HIV service delivery, costs to clients and providers, and perceived low quality of care. Conclusions The current evidence suggests that pharmacy‐delivered HIV services may be feasible to implement and acceptable to clients and providers in parts of sub‐Saharan Africa. However, limited evidence outside East Africa exists, as does limited evidence on the effectiveness of and costs associated with pharmacy‐delivered HIV services. More research of this nature is needed to inform the scale‐up of this new differentiated